NNovo Nordisk Read More Novo Nordisk’s Oral GLP-1 Assault Begins as Earnings Cloud Hovers Over the Stock2026-05-05 Novo Nordisk rolls out oral semaglutide for diabetes and weight loss as Q1 earnings loom, with stock down…